The SMARTube

"Pushing the immune system to its limits, but it works," says Samuel Gebert MBA. Dip. Biology, of BioSam, Müllheim, Germany.

SMARTube technology enables super-stimulation of lymphocytes, which leads to enhanced production of antibodies in vitro. This enables better and earlier detection of infections.

Photo: The SMARTube

There is a ‘window period’ of weeks and months from the time of HIV or HCV infection to the time of serum-conversion. Infected yet serum-negative individuals are infectious and their blood transmits the infection to unwary recipients. Infected individuals who are misdiagnosed as negative are a source in spreading the infection further. More complete detection is the key to curtailing the epidemic.
Antibody-based blood tests are independent of the location of the pathogen (virus) in the body, and thus can be positive through the whole course of the infection. In order to use the antibody’s powerful diagnostic potential we need to be able to detect the immune potential for making virus specific antibodies, independently of their expression in the body. Stimunology, using the SMARTube, does that. Thus it holds the key to better, more complete, earlier detection of HIV and HCV infections.
Stimunology means pushing the immune system to produce the antibodies that it knows how to make (by virtue of exposure to the virus) even before they are naturally produced in the  body. Stimunology is a proprietary, technology platform.
  The SMARTube is a simple to use, cost-effective blood pre-treatment device, for more complete, detection of HIV and HCV carriers. It is not a diagnostic test; it is just a test tube with a proprietary solution in which a small blood sample is incubated prior to testing for the presence of HIV and HCV specific antibodies using commercially available kits (both for screening and for confirmation).
  The system has been tested in controlled clinical trials in Israel, China, Mexico and Africa, and has been registered in EU (CE Mark) and in Israel. FDA registration for the USA is commencing.

15.11.2007

More on the subject:
Read all latest stories

Related articles

Photo

News • High-sensitivity blood test

New cancer testing method to make regular monitoring affordable

Scientists from Singapore discovered a novel low-cost method of testing for cancers. The test sequences heated clinical samples to isolate cancer-specific signatures found in a patient’s blood.

Photo

Sponsored • Disease management

Multiplex Testing: A Solution to Manage Surge in Respiratory Illnesses as Concerns over “Multi-demic” Rise

Eunsin Bae, M.D. specializes in laboratory medicine and leads the Institute of Clinical Research at Seegene Inc. Her research focuses on microbiology, molecular biology, and hematology. Dr. Bae is…

Photo

News • Appeal for sustainability

POCT: Why the medical sector must tackle its single-use diagnostic waste

During the Covid-19 pandemic, the use of these single-use diagnostics, or point-of-care tests has exploded. This is having major environmental consequences, experts point out.

Related products

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
ASP Lab Automation – SortPro Sample sorter

Sample Processing

ASP Lab Automation – SortPro Sample sorter

ASP Lab Automation AG
Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter Diagnostics
Subscribe to Newsletter